Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.

Abstract

Serum samples from 137 lung cancer patients were examined by RIA to evaluate the clinical efficacy of the new tumor marker, CYFRA 21-1, which could identify the soluble fragment of cytokeratin 19. The cut-off value was determined to be 2.2 ng/ml according to the receiver operating characteristic curve. The sensitivity, specificity and accuracy of the RIA… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.